Considering the tumor volume at sacrifice, we found the highest volume in both the anti-PD-1 and isotype control groups and the lowest volume in the concomitant treatment group (Fig. 2B, where all the numerous post hoc between-group differences are shown), which was even lower than that measured in the cisplatin group. The gene discussed is PDCD1; the disease is neoplasm.